Cheng-I Wang
Head of Antibody Development
Dr. Cheng-I Wang leads antibody development at Albatroz Therapeutics. He is also a Senior Principal Investigator at the Singapore Immunology Network. Antibodies created by his team at A*STAR, in infectious disease and cancer immunotherapy, have been licensed by multinational pharmaceutical companies.
Previously, Cheng-I founded Euchloe Bio (acquired by Tessa Therapeutics) and worked in drug discovery at several biopharma companies in the United States.
Cheng-I is also an Adjunct Associate Professor at the School of Biological Sciences, Nanyang Technological University. He holds a PhD in chemistry from Washington University, and did his postdoctoral training in pharmaceutical chemistry at the University of California, San Francisco.